Trials / Completed
CompletedNCT01817270
Immunogenicity and Safety Study of 2 Doses of Live Attenuated Varicella Vaccine
A Study to Evaluate the Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 368 (actual)
- Sponsor
- Changchun Keygen Biological Products Co., Ltd. · Academic / Other
- Sex
- All
- Age
- 1 Year – 3 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to observe the occurrence of adverse events, seroconversion rate and geometric mean titres(GMTs) of 2 doses of live attenuated varicella vaccine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Live Attenuated Varicella Vaccine |
Timeline
- Start date
- 2013-03-01
- Primary completion
- 2013-08-01
- Completion
- 2013-08-01
- First posted
- 2013-03-25
- Last updated
- 2013-10-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01817270. Inclusion in this directory is not an endorsement.